Shanghai Yaoyuan Biotechnology Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Shanghai China

Primary Industry

Biotechnology

About

Established in 2015 and based in Shanghai, China, Shanghai Yaoyuan Biotechnology Co., Ltd. is a biotechnology company that focuses on the development of immunotherapies. With a U.S. presence, the company focuses on developing therapies for hepatitis B, oncology and autoimmune diseases using genetics and artificial intelligence technologies. The company's current R&D platform and pipeline are built primarily on the piggyBac transposon technology of its founder, Professor Xu Tian. In May 2023, the company closed a round of series C funding. The company currently has two major platforms, IDInVivo ⁺ transposon-based genetic screening for direct discovery of new drug targets in living animals with intact immune systems, and MedChem5, a platform for drug molecule design using deep learning technologies. Currently, the company has developed drugs DF-003 and DF-006. DF-006 is an oral ALPK1 agonist that effectively activates hepatic innate immunity, and DF-003 is an oral ALPK1 kinase inhibitor that targets the treatment of renal disease, cardiovascular disease, and the rare ophthalmic genetic disease ROSAH. The company will use the series C funding to conduct clinical trials for the drug DF-006 and to advance the new first-in-class drug DF-003 to Phase I clinical trials.

Current Investors

Hanking Family Office, Detong Capital, BVCF Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.drug-farm.com

Verticals

Artificial Intelligence

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.